Preclinical Data Demonstrate Anti-Siglec-15 Treatment Reduced Bone Loss and Enhanced Bone Quality in Mice with Moderate-to-Severe Osteogenesis Imperfecta (OI)
Retrieved on:
Tuesday, October 17, 2023
Hospital for Special Surgery, Male, Cortex, Spectroscopy, Female, BMD, Bone, Bone disease, Osteogenesis imperfecta, Society, Mab, Hospital, American Society for Bone and Mineral Research, Osteoporosis, Cancer, Fracture, Osteoclast, Calvarial doughnut lesions-bone fragility syndrome, Mouse, S15, Porosity, Life, OI, Patient, Medical imaging, Birth control
These results support development of NC605 as a potential highly effective treatment for osteogenesis imperfecta, a rare disease in which bones easily fracture.
Key Points:
- These results support development of NC605 as a potential highly effective treatment for osteogenesis imperfecta, a rare disease in which bones easily fracture.
- Osteogenesis imperfecta is a rare disorder that results in high bone turnover, abnormal bone formation, bone fragility and recurrent fractures.
- There is no cure for OI and current anti-resorptive treatments increase bone mineral density (BMD) primarily by inhibiting bone loss; however, these agents also inhibit bone formation.
- Unlike anti-resorptive therapies, NC605 enhances osteoblast recruitment, resulting in overall enhanced bone quality.